Michael Wong
@michaelwong.bsky.social
Biotech venture creation and pharma partnerships. Company builder by practice, placental biologist by training. 🇨🇦
Recharged by the inspiring discussions with current and prospective partners at #JPM2025. Our industry undoubtedly has flaws but there are a lot of great people at the helm seeking to make a difference in drug discovery and healthcare.
Now back to the bitter cold week ahead in Boston…
Now back to the bitter cold week ahead in Boston…
January 20, 2025 at 2:11 PM
Recharged by the inspiring discussions with current and prospective partners at #JPM2025. Our industry undoubtedly has flaws but there are a lot of great people at the helm seeking to make a difference in drug discovery and healthcare.
Now back to the bitter cold week ahead in Boston…
Now back to the bitter cold week ahead in Boston…
Well, this has got to be one of the coolest and funniest gifts I’ve ever received.
December 20, 2024 at 2:20 AM
Well, this has got to be one of the coolest and funniest gifts I’ve ever received.
My 6 yr old wrote this tonight. Any guesses who “DT” is?
(I’m just glad I made the good list.)
(I’m just glad I made the good list.)
December 10, 2024 at 2:52 AM
My 6 yr old wrote this tonight. Any guesses who “DT” is?
(I’m just glad I made the good list.)
(I’m just glad I made the good list.)
Gotta love this city in the fall.
November 19, 2024 at 1:49 AM
Gotta love this city in the fall.
Small molecules remain dominant modality, but IRA fears and optionality of new modalities potentially slowly eroding deal activity.
Advanced modalities like Abs/biologics, conjugates, and oligos show continued growth.
Rapid decline in CGT deal volume perhaps due to ongoing industry challenges.
Advanced modalities like Abs/biologics, conjugates, and oligos show continued growth.
Rapid decline in CGT deal volume perhaps due to ongoing industry challenges.
November 17, 2024 at 3:36 AM
Small molecules remain dominant modality, but IRA fears and optionality of new modalities potentially slowly eroding deal activity.
Advanced modalities like Abs/biologics, conjugates, and oligos show continued growth.
Rapid decline in CGT deal volume perhaps due to ongoing industry challenges.
Advanced modalities like Abs/biologics, conjugates, and oligos show continued growth.
Rapid decline in CGT deal volume perhaps due to ongoing industry challenges.
Immunology and cardio-metabolism deals grow in prominence as top 35 pharma continues migration towards chronic disease, while rare disease and infectious disease deals have gradually become nearly obsolete.
Oncology showing plateau but remains dominant therapeutic area.
Oncology showing plateau but remains dominant therapeutic area.
November 17, 2024 at 3:36 AM
Immunology and cardio-metabolism deals grow in prominence as top 35 pharma continues migration towards chronic disease, while rare disease and infectious disease deals have gradually become nearly obsolete.
Oncology showing plateau but remains dominant therapeutic area.
Oncology showing plateau but remains dominant therapeutic area.
Total number of deals and total deal values at end of 2024 Q3 remain comparable to 2023, but a sharp decline seen in UPFRONT payments made (~$2B in 2024 vs. ~3B in 2023) – suggesting many Pharmas still willing to commit biobucks but are less willing (or capable) of making upfronts for early-stage.
November 17, 2024 at 3:36 AM
Total number of deals and total deal values at end of 2024 Q3 remain comparable to 2023, but a sharp decline seen in UPFRONT payments made (~$2B in 2024 vs. ~3B in 2023) – suggesting many Pharmas still willing to commit biobucks but are less willing (or capable) of making upfronts for early-stage.
Who’s making early-stage #biopharma deals in 2024?
I ran a quick analysis of the ~60 discovery and preclinical-stage strategic partnerships by top 35 Pharma in 2024 (Q1-Q3) and the results are fascinating…
A few snapshots here:
#biosky
I ran a quick analysis of the ~60 discovery and preclinical-stage strategic partnerships by top 35 Pharma in 2024 (Q1-Q3) and the results are fascinating…
A few snapshots here:
#biosky
November 17, 2024 at 3:36 AM
Who’s making early-stage #biopharma deals in 2024?
I ran a quick analysis of the ~60 discovery and preclinical-stage strategic partnerships by top 35 Pharma in 2024 (Q1-Q3) and the results are fascinating…
A few snapshots here:
#biosky
I ran a quick analysis of the ~60 discovery and preclinical-stage strategic partnerships by top 35 Pharma in 2024 (Q1-Q3) and the results are fascinating…
A few snapshots here:
#biosky